Clinical trial
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to…
NCT00394836 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00394836 |
|---|---|
| Title | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab |
| Official title | A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular |
| Intervention type | Drug |
| Interventions | Ofatumumab |
| Enrollment | 116 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Sep 1, 2013 |
| First posted | Nov 1, 2006 |
| Last update posted | Jan 29, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: